Back جريفولز Arabic قریفولس AZB Grifols Catalan Grifols German Grifols Spanish Grifols Basque گریفولس Persian Grifols French Grifols Italian グリフォルス Japanese
 | |
| Company type | Public |
|---|---|
| ISIN | ES0171996012 |
| Industry | Pharmaceuticals, chemicals |
| Founded | 1940 |
| Headquarters | Barcelona, Spain |
Key people | |
| Products | Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals |
| Revenue |  €6.064 billion (2022) |
| €805.7 million (2022) | |
| €271.1 million (2022) | |
| Total assets | €21.53 billion (2022) |
| Total equity | €8.457 billion (2022) |
Number of employees | 26,314 (2022) |
| Website | grifols |
| Footnotes / references [1] [2] | |
_1.jpg)
Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a global healthcare company and manufacturer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,000employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.[3]
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide,[4][5] and other biopharmaceutical solutions, the company is also a leader in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Its portfolio of solutions is designed to enhance safety from donation to transfusion. Grifols also provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. Additionally, the company supply tools, information and services that enable hospitals, pharmacies and healthcare professionals to deliver expert medical care.[6]
Grifols is focused on treating chronic, rare and prevalent conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.[7]
- ^ "2022 Annual Report (Form 20-F)". US Securities and Exchange Commission. Retrieved 2023-04-18.
- ^ "Grifols appoints new CEO Nacho Abia to the board". Nasdaq. Retrieved 2024-04-03.
- ^ "GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus". BioSpace. 2024-11-19. Retrieved 2025-02-21.
- ^ Smyth, Sharon; Gore, Gareth (23 June 2008). "Santander, Sabadell, Sol Melia, Urbas: Iberia Preview". Bloomberg. Archived from the original on 23 October 2012. Retrieved 2009-01-18.
- ^ "Novartis Sells Blood Transfusion Dx Unit to Grifols". Genetic Engineering & Biotechnology News (Paper). Vol. 33, no. 21. December 2013. p. 10.
- ^ "Plasma Derived Therapies Market (Immunoglobulin, Hemophilia, Specialty, and Albumin) Insights & Forecast 2024-2028, Featuring CSL, Grifols, Takeda Pharmaceutical, Octapharma, Kedrion & ADMA Biologics - ResearchAndMarkets.com". Business Wire. June 13, 2024.
- ^ "Grifols 2023 Annual Report on Form 20-F filed with the SEC". AP News. 2024-04-19. Retrieved 2025-02-21.